The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment by Lee, Jung Il
The Korean Journal of Hepatology 2010;16:418-419
DOI: 10.3350/kjhep.2010.16.4.418 The  Korean Journal of  Hepatology Elsewhere
The  effect  of  sorafenib  on  hepatic  stellate  cells:
implication  of  its  effect  on  tumor  microenvironment
Jung Il Lee
Department of Internal Medicine, Division of Gastroenterology, Inha University School of Medicine, Incheon, Korea
Keywords: Sorafenib; Hepatocellular carcinoma; Stellate cell
Abbreviations:  HCC, hepatocellular carcinoma; VEGFR, vascular endothelial growth factor  receptor; PDGFR, platelet derived growth factor  receptor; 
HSC, hepatic  stellate  cell;  DMN,  dimethylnitrosamine; ALT, alanine  aminotransferase
Corresponding author:  Jung  Il  Lee
Department of  Internal  Medicine,  Division  of  Gastroenterology, Inha  University School  of  Medicine,  7-206  3-ga,  Sinheung-dong, Jung-gu,  Incheon 
400-711, Korea
Tel.  +82-32-890-2548, Fax.  +82-32-890-2549, E-mail;  mdflorence@inha.ac.kr
Copyrights Ⓒ  2010 by The Korean Association for the Study of the Liver
The Korean Journal of Hepatology∙pISSN: 1738-222X eISSN: 2093-8047
New insights into the antifibrotic effects of sorafenib on 
hepatic stellate cells and liver fibrosis. 
Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. 
J hepatol 2010;53:132-144.
Sorafenib is a multiple receptor tyrosine kinase inhibitor that 
has been shown to improve the survival of patients with 
advanced hepatocellular carcinoma (HCC).
1,2 It acts by blocking 
the receptor tyrosine kinases such as vascular endothelial growth 
factor receptors (VEGFR), platelet derived growth factor re-
ceptor (PDGFR), c-Kit, fibroblast growth factor receptor-1, and 
the serine/threonine kinase RAF, thereby repressing cell pro-
liferation and angiogenesis.
3,4 The drug is currently considered 
as the standard of care in patients with advanced HCC and pre-
served liver function.
5 Unfortunately, majority of patients with 
advanced HCC still die from the disease despite of the sorafenib 
treatment. In order to satisfy the unmet need in treating advanced 
HCC, additional investigation is required to clarify the molecular 
pathogenesis of HCC. Understanding the mechanism of action of 
sorafenib, both on tumor and non-tumor tissue, would be a step 
forward. 
Multiple kinases that are suppressed by sorafenib not only 
involve in the survival of tumor cells themselves but also that of 
other cells surrounding the tumor tissue. There have been grow-
ing evidences that this surrounding tissue, so called the tumor 
microenvironments, would play an important role in tumore-
genesis, tumor invasion and metastasis.
6,7  The tumor micro-
environments of HCC include cells such as hepatic stellate cells 
(HSCs) and immune cells, growth factors, proteolytic enzymes, 
extracellular matrix and inflammatory cytokines. 
HSCs are activated in response to liver damage. The repeated 
injury would result in liver fibrosis.
8 In addition, activated HSCs 
may infiltrate the stroma of liver tumors and localize around 
tumor sinusoids, fibrous septa and capsules.
9 It has been reported 
that the media collected from HSCs induced proliferation and 
migration of HCC cells, cultured in monolayers. It also has been 
demonstrated that simultaneous in vivo implantation of HSCs 
and HCC cells into nude mice promoted tumor growth and 
invasiveness when necrosis was inhibited.
10
The study by Wang et al
11reported the effect of sorafenib on 
HSCs in vitro and liver fibrosis in vivo. On two separate liver 
fibrosis animal models, one induced by bile duct ligation and the 
other chemically induced by intraperitoneal dimethylnitrosamine 
(DMN), sorafenib attenuated liver fibrosis. Liver fibrosis was 
histologically evaluated by Masson’s trichrome collagen staining 
and quantification of collagen production. However, the behav-
ior of HSCs upon sorafenib treatment in vivo was not fully inves-
tigated in this particular study. The effect of sorafenib on HSC 
proliferation and apoptosis were shown only on HSC cell lines. 
Although the assumption could be made that the anti-fibrotic 
effect was caused by sorafenib on HSCs, being the key player in 
liver fibrosis, more solid evidence would be preferred. This evi-Jung Il Lee. Sorafenib and hepatic stellate cell  419
dence came from the study by Hennenberg et al
12 that was 
recently published. The study showed the decreased number of 
α -smooth muscle actin positive cells in bile duct ligated rats after 
sorafenib administration.
12
Both Wang and Hennenberg studies emphasized the role of 
sorafenib as antifibrotic agent. These studies support the pre-
vious investigations reporting the beneficial effect of sorafenib 
on portal hypertension.
13,14 However, translation and clinical 
application of these results in treating portal hypertension and 
cirrhosis still have to undergo very carefully. In vivo studies, in-
cluding the one performed by Wang Y et al, showed aggravation 
in  liver  parameters  such  as  serum  alanine  aminotransferase 
(ALT) by certain concentration of sorafenib. Instead, the effect of 
sorafenib on HSCs rather implies that sorafenib not only sup-
presses the tumor cells themselves but also attenuates the tumor 
microenvironments that might have cross-talk with the cancer 
cells. Evaluating the effect of sorafenib on HSCs surrounding 
HCC would provide better perspective on this. In addition, 
understanding the behavior of sorafenib on the tissue surround-
ing the tumor might give more clues for pathogenesis of HCC 
thus better strategy against HCC. There has been growing num-
ber of reports over the recent years that emphasized the role of 
tumor  microenvironments.  It  appears  that  tumor  cells,  once 
thought to be autonomous, seem to depend on angiogenesis, in-
flammatory cells and fibroblasts.
15-17 Therefore it would be ideal 
if the treatment were to target tumor-microenvironment inter-
action that stimulated tumor progression, invasion and meta-
stasis as well as hepatocarcinogenesis. Further studies evaluating 
how sorafenib meet this goal would be a great resource in devel-
oping new drugs that could be used alone or in combination with 
sorafenib.
In summary, evidences that show anti-fibrotic effect of sor-
afenib through suppressing HSCs has been reported. Implication 
and use of this information may need further contemplation.
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